- Raised $3.4M funding round, Jan 2021
- Raised $1.4M funding round, Feb 2019
- Raised $54k grant, May 2016
About
Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's Todos Biochemical Infrared Analyses comprise proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test is a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies.
Funding history · 3 rounds · $3.5M total
Q&A
- What is Todos Medical's primary focus?
- Todos Medical focuses on engineering life-saving diagnostic solutions for the early detection of various cancers and neurodegenerative disorders like Alzheimer's disease.
- What is Todos Medical's core cancer screening technology?
- Todos Medical's core cancer screening technology is the Todos Biochemical Infrared Analyses, which uses proprietary cancer-screening technology via peripheral blood analysis to examine cancer's influence on the immune system.
- What is the status of Todos Medical's cancer screening tests?
- Todos Medical's two internally developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe.
- What is the Lymphocyte Proliferation Test being developed by Todos Medical?
- The Lymphocyte Proliferation Test is a diagnostic blood test being developed by Todos Medical to determine the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle, for early detection of neurodegenerative disorders.
- What is Todos Medical's involvement with COVID-19 test kits?
- Todos Medical has entered into distribution agreements with companies to distribute various novel coronavirus (COVID-19) test kits, including PCR testing kits and antibody testing kits from multiple international suppliers.
- When was Todos Medical founded?
- Todos Medical was founded in November 2009.
- How many employees does Todos Medical have?
- Todos Medical has 1-10 employees.
- What was Todos Medical's most recent funding round?
- In January 2021, Todos Medical raised $3,400,000 from The Yozma Group.
- What is Todos Medical's current market status?
- Todos Medical is a public company, having gone public on OTCBB in February 2016.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | todosmedical.com |
|---|---|
| linkedin.com/company/8557149 | |
| facebook.com/todosmedical | |
| YouTube | youtube.com/channel/UCnJCmQ1gKKiZTU6m8lL2EOg |
| Wikidata | wikidata.org/wiki/Q113530730 |
Identifiers & details
| Founded | 2009-11 |
|---|---|
| Employees (exact) | 7 |
| Offices | New York |
| Market cap | $21K |
| Status reason | Public on OTCBB on Feb 2016; |
| Wikidata QID | Q113530730 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | todosmedical.com |
|---|
Wikidata
| QID | Q113530730 |
|---|
Certificate / subdomain footprint
| Subdomains | 11 |
|---|